The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women (MK-0217A-352)

Study identification

• EU PAS number:
  EUPAS17909
• Study ID:
  19310
• Official title and acronym:
  The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women (MK-0217A-352)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.
• Study status:
  Finalised

Research institutions and networks

Institutions

Merck Sharp & Dohme LLC

United States

Study timelines

Date when funding contract was signed

Actual: 24/07/2009

Study start date

Actual: 26/02/2010

Data analysis start date

Actual: 16/02/2012

Date of final study report

Actual: 31/03/2012

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme Corp.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

MK-0217A-352NCT01077817